Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02016105 · ClinicalTrials.gov registry record · Phase 3
Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Adalimumab (GP2017) and Humira
A Phase 3 study, sponsored by Sandoz.
- Completed
- Registry status
- Phase 3
- Development phase
- 465
- Enrollment target
NCT02016105 is a Phase 3 study that has completed, run by Sandoz. The registered enrollment target is 465 participants.
The verdict
NCT02016105, a Phase 3 study, has completed, sponsored by Sandoz.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 465 participants
- Enrollment target
Study Summary
The aim of the study is to demonstrate equivalent efficacy and similarity in the safety profile of GP2017 and Humira® in patients with moderate to severe chronic plaque-type psoriasis.
Interventions
- DRUG GP2017 Adalimumab
- DRUG Humira ® Adalimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 465 participants |
| Start Date | 2013-12 |
| Est. Completion | 2016-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02016105
The ClinicalTrials.gov registry entry for NCT02016105 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 465 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sandoz, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which GP2017 Adalimumab is the first listed.
NCT02016105 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02016105 about?
NCT02016105 is a clinical study titled "Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Adalimumab (GP2017) and Humira". The aim of the study is to demonstrate equivalent efficacy and similarity in the safety profile of GP2017 and Humira® in patients with moderate to severe chronic plaque-type psoriasis.
What is the current status of trial NCT02016105?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 465 participants. The study started on 2013-12. Estimated completion is 2016-02.
What interventions are being tested in trial NCT02016105?
The interventions under investigation include: GP2017 Adalimumab (DRUG), Humira ® Adalimumab (DRUG).
Who is sponsoring clinical trial NCT02016105?
This trial is sponsored by Sandoz, which has 29 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.